TN ER-/PR-/HER2- Breast Cancer
1 clinical trials · Condition
◉ Watch TN ER-/PR-/HER2- Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer (NCT03981705) | Masonic Cancer Center, University of Minnesota | 2019-08-08 |
Track TN ER-/PR-/HER2- Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.